Month: October 2025

CN Declares Fourth-Quarter 2025 Dividend

Written by Customer Service on October 31, 2025. Posted in Dividend Reports And Estimates.

MONTREAL, Oct. 31, 2025 (GLOBE NEWSWIRE) — CN (TSX: CNR) (NYSE: CNI) announced today that its Board of Directors has approved a fourth-quarter 2025 dividend on the Company’s common shares outstanding. A quarterly dividend of eighty-eight and three-quarter cents (C$0.8875) per common share will be paid on December 30, 2025, to shareholders of record at the close of business on December 9, 2025. About CNCN powers the economy by safely transporting more than 300 million tons of natural resources, manufactured products, and finished goods throughout North America every year for its customers. With its nearly 20,000-mile rail network and related transportation services, CN connects Canada’s Eastern and Western coasts with the U.S. Midwest and the U.S. Gulf Coast, contributing to sustainable trade and the prosperity of the communities...

Mesa Air Group enters into an Amendment to its Loan Agreement with the United States Treasury and Provides Update to its Pending Merger with Republic Airways

Written by Customer Service on October 31, 2025. Posted in Mergers And Acquisitions.

US Treasury Loan Update PHOENIX, Oct. 31, 2025 (GLOBE NEWSWIRE) — Mesa Air Group, Inc. (NASDAQ: MESA) (“Mesa” or the “Company”) today announced that it has entered into an Amendment (the “Amendment”) to its Loan and Guarantee Agreement, dated as of October 30, 2020 (as theretofore amended, the “Loan Agreement”), among the Company, Mesa Airlines, the Guarantors party thereto from time to time, Jefferies Capital Services, LLC (as successor in interest to the United States Department of the Treasury) (the “Lender” or “Jefferies”), and The Bank of New York Mellon as Administrative Agent and Collateral Agent (the “Agents”) (collectively, the “Parties”). Under the terms of the Amendment, Jefferies agreed to:extend the Maturity Date of the Loan Agreement from October 30, 2025 to November 28, 2025, subject to the Company’s further right...

OROCO RESOURCE CORP. PROVIDES FINANCING UPDATE

Written by Customer Service on October 31, 2025. Posted in Public Companies.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, Canada, Oct. 31, 2025 (GLOBE NEWSWIRE) — Oroco Resource Corp. (TSX-V: OCO, OTCQB: ORRCF) confirms that the non-brokered private placement financing, announced on September 25, 2025, is proceeding as planned and will be completed within the necessary regulatory timeframe. The Offering is for up to 18,000,000 Units at a price of US$0.20 per Unit (for aggregate gross proceeds of up to US$3.6 million, with an anticipated minimum of US$2.0 million). Each Unit consists of one common share (a “Unit Share”) and one-half of one common share purchase warrant (the “Warrant”). Each whole Warrant entitles the holder to purchase one common share at US$0.30 within 24 months of the Unit issue date. This financing was arranged to accommodate...

Costamare Inc. Sets the Date for Its Third Quarter 2025 Results Release, Conference Call and Webcast

Written by Customer Service on October 31, 2025. Posted in Public Companies.

Earnings Release: Tuesday, November 4, 2025, Before Market OpensConference Call and Webcast: Tuesday, November 4, at 8:30 a.m. ET MONACO, Oct. 31, 2025 (GLOBE NEWSWIRE) — Costamare Inc. (NYSE:CMRE) (the “Company”), announced today that it will release its results for the third quarter ended September 30, 2025 before the market opens in New York on November 4, 2025. Conference Call Details: On Tuesday, November 4, 2025 at 8:30 a.m. ET, Costamare’s management team will hold a conference call to discuss the financial results. Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 1-844-887-9405 (from the US), 0808-238-9064 (from the UK) or +1-412-317-9258 (from outside the US). Please quote “Costamare”. A replay of the conference call will be available until November 11,...

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025

Written by Customer Service on October 31, 2025. Posted in Public Companies.

PRINCETON, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November.2025 UBS Global Healthcare Conference in Palm Beach Gardens, FL on Monday, November 10, 2025, at 2:45 p.m. ET Jefferies Global Healthcare Conference 2025 in London, U.K. on Tuesday, November 18, 2025, at 4:30 p.m. GMTA live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare...

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

Written by Customer Service on October 31, 2025. Posted in Public Companies.

Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA Patients randomized to either 10 or 20 mg/kg of muzastotug, in combination with KEYTRUDA with up to 30 patients per arm Company anticipates trial completion in early 2027, and potential updates in 2026 Additional updates from the ongoing Phase 1b/2 trial with muzastotug, previously reported at ASCO 2025, are anticipated in the coming months SAN DIEGO and SUZHOU, China, Oct. 31, 2025 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that the first patient has been dosed in its randomized, open label Phase 2 study of muzastotug in combination with Merck’s (known as MSD outside of...

Upstream Bio to Participate in Upcoming November Investor Conferences

Written by Customer Service on October 31, 2025. Posted in Public Companies.

WALTHAM, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) — Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in November:2025 Truist Securities BioPharma Symposium, New York, NYThursday, November 6, 2025, Panel – 8:10 a.m. ET Stifel 2025 Healthcare Conference, New York, NYTuesday, November 11, 2025, Presentation – 9:20 a.m. ETTD Cowen Immunology and Inflammation Summit, VirtualWednesday, November 12, 2025, Fireside Chat – 10:30 a.m. ETLive webcasts of the Stifel and Cowen presentations will be available under the Events tab on the Investors section of...

BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers

Written by Customer Service on October 31, 2025. Posted in Public Companies.

Randomized controlled trial results published in the International Journal of Tissue Repair demonstrate BioRetain® allografts significantly improve probability of achieving lasting wound closure versus standard of care POMPANO BEACH, Fla., Oct. 31, 2025 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced top-line results of the Company’s clinical trial evaluating BioRetain® – Processed Amnion Chorion (BR-AC) versus standard of care for patients with non-healing diabetic foot ulcers (DFUs), as published in the International Journal of Tissue Repair. Top-Line ResultsBR-AC achieved superior clinical outcomes in this patient population. The...

NANO Nuclear Senior Executives to Present at Upcoming November Nuclear Industry Conferences Including ADIPEC 2025, the World’s Largest Energy Conference

Written by Customer Service on October 31, 2025. Posted in Public Companies.

NANO Nuclear Energy Inc.Figure 1 – NANO Nuclear Energy Inc. Founder and Chairman Jay Yu will participate in multiple speaking sessions from November 3-6 at ADIPEC 2025 in Abu Dhabi, UAE, the world’s largest energy event. ADIPEC will host more than 16,500 delegates, 1,800 speakers, and over 205,000 attendees for high-level discussions shaping the future of energy.New York, N.Y., Oct. 31, 2025 (GLOBE NEWSWIRE) — NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that members of its senior executive team will participate in several upcoming industry conferences, including ADIPEC 2025, the world’s largest energy event. Scheduled for November 3-6, 2025, in Abu Dhabi, UAE. ADIPEC...

Carlyle Secured Lending, Inc. Announces Intent to Redeem All Outstanding 8.20% Notes Due 2028

Written by Customer Service on October 31, 2025. Posted in Public Companies.

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) — Carlyle Secured Lending, Inc. (the “Company”) (Nasdaq: CGBD) today announced that it intends to redeem all $85,000,000 aggregate principal amount of its outstanding 8.20% Notes due 2028 (the “2028 Notes”) on December 1, 2025 (the “Redemption Date”). A notice of redemption will be mailed to all registered holders of the 2028 Notes by U.S. Bank Trust Company, National Association, as successor trustee to The Bank of New York Mellon Trust Company, N.A (the “Trustee”), in accordance with the terms of the Indenture, dated as of November 20, 2023 (the “Base Indenture”), between the Company and the Trustee, and the First Supplemental Indenture, dated as of November 20, 2023 (together with the Base Indenture, the “Indenture”). The redemption...

Month: October 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals